BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the second quarter ended June 30, 2026 and provide a corporate update, before the financial markets open on Thursday, August 6, 2026.
The Company will host a conference call and a live webcast to review the second quarter financial results and provide a corporate update on Thursday, August 6, 2026, at 8:30 am ET, which can be accessed by visiting this registration link. The live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website www.praxismedicines.com.
A replay of the second quarter earnings webcast will be available on Praxis’ Events & Presentations page of the company’s website after each event for approximately 90 days.
About Praxis
Praxis Precision Medicines is a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four late-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, Instagram, LinkedIn and Twitter/X.
Investor Contact: Praxis Precision Medicines investors@praxismedicines.com 857-702-9452 Media Contact: Dan Ferry LifeSci Advisors Daniel@lifesciadvisors.com 617-430-7576
